Anzalone Christopher Richard sold ARWR
March 3, 2025 · Form 4 insider transaction
Anzalone Christopher Richard sold 166,667 shares of Arrowhead Pharmaceuticals, Inc. at $18.03 per share, a transaction worth $3.01M. The trade was recorded as open-market sale under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 2 days after the transaction.
Direction
Disposed (sell-side)
Shares
166,667
Price
$18.03
Total value
$3.01M
InsiderAnzalone Christopher Richard
Role—
SecurityCommon Stock
Transaction codeS: Open-market sale
Transaction dateMarch 3, 2025
Filing dateMarch 5, 2025
Shares owned after3,907,135
OwnershipDirect
10b5-1 planYes
AmendedNo
Footnotes
The exercise of non-qualified stock options and sale was made as the stock options were approaching their expiration date. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.